1. Background
2. Objectives
3. Methods
3.1. Study Designs
3.2. Study Population
3.3. Severity of COVID-19
3.4. Interventions and Data Collection
3.5. Chest Computed Tomography Findings
3.6. Statistical Analysis
4. Results
4.1. Study Population and Clinical Data
| Variables | Values |
|---|---|
| Patient demographics | |
| Total patients | 47 (100) |
| Male | 34 (72.4) |
| Female | 13 (27.6) |
| Age (y); range | 25 - 87 |
| Age (y); mean ± SD | 62 ± 14 |
| Laboratory test | |
| C-reactive protein (mg/L; normal range 0.00 - 5.90) | |
| Increased | 44 (93) |
| Normal | 1 (2) |
| CRP mean level | 76 |
| White blood cell (× 10³/mm³; normal range 4.4 - 11) | |
| Increased | 14 (30) |
| Decreased | 5 (10) |
| Normal | 28 (60) |
| Lymphocyte (× 10³/mm³ normal range 1.5 - 3.0) | |
| Increased | 4 (9) |
| Decreased | 31 (66) |
| Normal | 12 (25) |
| Neutrophil (× 10³/mm³, normal range 1.5 - 8.0) | |
| Increased | 30 (64) |
| Decreased | 0 (0) |
| Normal | 17 (36) |
Abbreviation: CRP, C-reactive protein.
4.2. Chest Computed Tomography Scan Findings
| Variables | Score 1 | Score 2 | Score 3 | Score 4 | Score 5 |
|---|---|---|---|---|---|
| RUL | 4 (1 - 8) | 10 (6 - 15) | 18(12 - 24) | 12 (8 - 16) | 0 |
| RML | 6 (3 - 9) | 15 (10-20) | 14 (9 - 20) | 4 (1 - 8) | 3 (1 - 6) |
| RLL | 2 (0 - 5) | 9 (5 - 14) | 25 (19 - 30) | 6 (3 - 10) | 4 (2 - 6) |
| LUL | 7 (4 - 10) | 14 (9 - 19) | 12 (7 - 18) | 10 (6 - 14) | 1 (0 - 4) |
| LLL | 5 (2 - 8) | 10 (6 - 15) | 20 (14 - 26) | 9 (5 - 13) | 3 (1 - 6) |
Abbreviations: RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.
| Features | No. (%) | 95% CI |
|---|---|---|
| CT appearance | ||
| GGO | 26 (55) | (24 - 26) |
| Consolidation | 14 (30) | (9 - 19) |
| Equal GGO/consolidation | 9 (19) | (5 - 14) |
| Reverse halo | 1 (2) | (0 - 4) |
| Cavity | 0 | 0 |
| Nodule | 0 | 0 |
| Pleural effusion | 10 (21) | (6 - 15) |
| Pericardial effusion | 3 (6) | (1 - 7) |
| Distribution | ||
| Peripheral | 35 (74) | (32 - 36) |
| Perihilar | 1 (2) | 2 (0 - 4) |
| Peribronchovascular | 36 (76) | (34 - 36) |
Abbreviations: CT, computed tomography; GGO, ground-glass opacity; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.
| CT Features Sub-analysis | Patients | |
|---|---|---|
| Number of involved lobes | Values | 95% CI |
| 0 | 0 | NA |
| 1 | 0 | NA |
| 2 | 2 (4.3) | (0 - 6) |
| 3 | 1 (2.1) | (0 - 4) |
| 4 | 4 (8.5) | (1 - 9) |
| 5 | 40 (85) | (38 - 40) |
| Frequency of lobe involvement | ||
| RUL | 44 (94) | (39 - 46) |
| RML | 42 (90) | (37 - 45) |
| RLL | 46 (98) | (43 - 47) |
| LUL | 44 (94) | (39 - 46) |
| LLL | 47 (10) | (45 - 47) |
| GGO pattern | ||
| Crazy paving | 4 (8) | (1 - 8) |
| Round opacities | 11 (23) | (7 -14) |
| Linear opacities | 4 (8) | (1 - 8) |
| Nonspecific | 16 (34) | (14 - 16) |
Abbreviations: CT, computed tomography; GGO, ground-glass opacity; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.
